Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Docetaxel in EGFR-mutant Advanced NSCLC
NCT04619563Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04619563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619563.